CompletedPhase 2NCT00003849

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Thomas E. Witzig, MD
Mayo Clinic
Intervention: rituximab(biological)
Enrollment: 39 enrolled
Eligibility: 18 years · All sexes
Timeline: 1999 – 2008

Study locations (21)

CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
CCOP - Carle Cancer Center, Urbana, Illinois, United States
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
CCOP - Wichita, Wichita, Kansas, United States
CCOP - Ochsner, New Orleans, Louisiana, United States
CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States
CCOP - Duluth, Duluth, Minnesota, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
CentraCare Clinic, Saint Cloud, Minnesota, United States
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
+6 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003849 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials